CUTAQUIG

Cutaquig is prescribed for the treatment of Primary Immunodeficiency (PI) disease in adults and pediatric patients aged 2 years and older. PI encompasses various forms, with the most prevalent types resulting in the inability to produce crucial antibodies that defend the body against infections.

CUTAQUIG is a 16.5% immune globulin solution for subcutaneous infusion. It is used as replacement therapy for primary humoral immunodeficiency in adults and pediatric patients aged 2 years and older.

Cutaquig is composed primarily of immunoglobulin G (IgG), which includes a wide range of antibodies that target various infectious agents. These IgG antibodies are representative of those found in the general population. The product is typically derived from a collection of plasma donations, totaling at least 1000 contributions.

This condition is referred to as “humoral immunodeficiency.” IVIG is administered to supplement the antibodies that your body is unable to produce naturally. These antibodies typically remain effective for several weeks to months, aiding your body in combating a wide range of infections before they escalate into a serious condition (or even before you are aware of their presence).

IVIg regulates the activation and functions of B and T lymphocytes, counteracts harmful autoantibodies, disrupts antigen presentation, and exerts a potent anti-inflammatory effect through its interactions with the complement system, cytokines, and endothelial cells.

Symptoms include bloody urine, reduced urination, fever, high blood pressure, increased thirst, loss of appetite, lower back pain, and nausea or vomiting.

In these exceptional cases, IVIg has the ability to prevent the individual’s own white blood cells from attacking and destroying platelets or red blood cells, leading to autoimmune thrombocytopenia and autoimmune hemolytic anemia, respectively. Additionally, IVIg can have a positive impact on immune system functioning.

Hizentra and other human immune globulin products have the potential to cause serious kidney problems, which can be life-threatening.

Immunoglobulin therapy is a medical procedure that enhances the concentration of antibodies in the bloodstream. This therapy involves the administration of antibodies, which are proteins naturally produced by the body, to aid in combating lung infections, which are frequently the initial site of infection.

IVIg and pathogen-specific hyperimmune IVIg prophylaxis are recommended for modifying or preventing certain viral syndromes such as hepatitis A, hepatitis B, measles, varicella, and rabies. Additionally, specific immunoglobulins may be prescribed to prevent tetanus and botulism in high-risk patients.

Hizentra is a prescribed medication for the treatment of primary immune deficiency (PI) in patients aged 2 and above, as well as for the maintenance therapy of chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.

If you experience reduced urination, sudden weight gain, or swelling in your legs, it is important to promptly inform your doctor as these could be indications of a serious adverse reaction to Hizentra. These symptoms may be signs of a kidney problem and should be reported immediately.

Hizentra is classified as an immunoglobulin medication and is primarily prescribed for the treatment of primary immunodeficiency and nerve conditions like demyelinating polyneuropathy. In this article, we will delve deeper into the uses and potential side effects of Hizentra.

Please select a new site for infusion that is at least 1 inch away from the previous site. Suitable options for infusion sites include the stomach, thighs, upper arms, and hips.

The price of a 5 milliliter supply of Hizentra subcutaneous solution 20% can vary, but it is typically around $235, depending on the pharmacy you choose.

If you experience a headache, upset stomach, fever, nausea, diarrhea, sore throat, cough, or pain, it is important to inform your doctor or pharmacist immediately if any of these symptoms persist or worsen.

The infusion time can vary depending on the dose and frequency prescribed by your healthcare provider. However, based on clinical trials, the median infusion time for PI is approximately 1.5-2 hours, while for CIDP it is about 1 hour.

IgRT infusions can be given either subcutaneously (SCIg) or intravenously (IVIg). Both methods have similar antibody activity.

Cancers like B-cell chronic lymphocytic leukemia (B-cell CLL) and multiple myeloma (MM) result in humoral immunosuppression, and IVIG therapy is beneficial for these conditions. Additionally, IVIG therapy is also beneficial for conditions involving B-cell depleting therapies, such as lymphoma, as well as geriatric patients experiencing recurrent infections.

Immunoglobulin (Ig) replacement therapy is the established treatment for individuals with antibody deficiencies. It involves administering Ig either intravenously (IVIG) or subcutaneously (SCIG) to replace the deficient antibodies in the patient’s body.

Hizentra is meant to be administered subcutaneously using an infusion pump. It should be infused in the abdomen, thigh, upper arm, and/or lateral hip. Multiple injection sites can be used for a Hizentra dose. You can use up to 4 sites at the same time or up to 12 sites consecutively per infusion.

After about 8-10 weeks, many individuals begin to observe a reduction in local reactions. As time goes on, the skin will become accustomed to the repeated infusions, resulting in a decrease in local reactions.

Prescription for immune globulin administered subcutaneously.

CUTAQUIG is designed to be administered subcutaneously using an infusion pump and compatible syringe(s). It can be simultaneously infused into up to 6 different sites, with each site being at least 2 inches (5 cm) apart. It is important to rotate the infusion sites between each administration.

Each vial of 24 ml contains 4 grams of human normal immunoglobulin, while each vial of 48 ml contains 8 grams. The maximum IgA content in each vial is 300 micrograms per milliliter. The immunoglobulin is derived from the plasma of human donors.

During therapy, a healthcare provider will administer prepared immunoglobulin by infusing it into your veins. They will use a needle to access your vein, allowing the medicine to flow from a bag through a tube and into your arm. The entire process typically takes approximately 2 to 4 hours.

Cutaquig is formulated with maltose and polysorbate 80 (PS80) as excipients.

Ig replacement therapy can be administered either intravenously (IVIG) or subcutaneously (SCIG). It is important to customize the therapy to suit the patient’s specific requirements. There are various treatment options available, and it is advisable for individuals to have a comprehensive discussion with their healthcare providers to explore these options.

To administer Flebogamma DIF 50 mg/ml intravenously, start with an initial infusion rate of 0.01 – 0.02 ml/kg/min for the first thirty minutes. Refer to section 4.4 for more information. If any adverse reactions occur, either decrease the rate of administration or stop the infusion altogether.

Patients who are able to tolerate the 5% concentration at a rate of 4 mL/kg/Hr can begin receiving the 10% concentration at a lower rate of 0.5 mL/kg/Hr. If there are no negative reactions, the rate can be gradually increased up to a maximum of 8 mL/kg/Hr.

IVIg is administered via intravenous infusion, which involves a drip into a vein. Alternatively, if the purpose is solely to boost immunoglobulin levels after other treatments, it may be given as an injection into a muscle. It is necessary to visit a hospital for each treatment.

Polygam S/D is utilized in the treatment of patients diagnosed with primary humoral immunodeficiency (PI), idiopathic thrombocytopenic purpura (ITP), chronic immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy (CIDP), or dermatomyositis (DM).

CUTAQUIG is a 16.5% immune globulin solution for subcutaneous infusion (IGSC). It is used as replacement therapy for primary humoral immunodeficiency (PI) in adults and pediatric patients aged 2 years and older.

You may experience mild swelling, redness, or itching at the injection site, which should improve as your body becomes accustomed to the medication. You may also experience headache, upset stomach, fever, nausea, diarrhea, sore throat, cough, or pain. If any of these symptoms persist or worsen, it is important to inform your doctor or pharmacist right away.

CUTAQUIG is a 16.5% immune globulin solution for subcutaneous infusion. It is used as replacement therapy for primary humoral immunodeficiency in adults and pediatric patients aged 2 years and older.

Cutaquig is a high-concentration SCIg therapy, containing 16.5% solution of Immune Globulin Subcutaneous [Human] – hipp. Infusions of Cutaquig typically have a short duration, usually lasting under an hour.

Infusion Number: First 2 Infusions
Volume (mL/site):
– 7-16 years: ‰¤15 mL
– 2-6 years: ‰¤10 mL
Rate per site (mL/hr):
– Adults 17 years: ‰¤20 mL

When IG is administered subcutaneously, it enters the circulation at a slower rate compared to IVIG. This leads to more stable serum IG levels and avoids the “peak” IG levels seen with IVIG infusions. There is no evidence to suggest that either method of administration is more effective than the other.

Cutaquig is composed primarily of immunoglobulin G (IgG), which includes a wide range of antibodies that target various infectious agents. These IgG antibodies are representative of those found in the general population. The product is typically derived from a collection of plasma donations, totaling at least 1000 contributions.

Subcutaneous infusion, also known as hypodermoclysis, involves the administration of fluids into the subcutaneous space using small-gauge needles. These needles are usually inserted into the thighs, abdomen, back, or arms.

The amount of 20% SCIG product delivered per injection site can vary, typically ranging from 20 to 25 mL, based on factors such as the patient’s age and weight.

6 mL (1 g) NDC Number – Carton: 68982-810-01
NDC Number – Vial: 68982-810-81
12 mL (2 g) NDC Number – Carton: 68982-810-03
NDC Number – Vial: 68982-810-83
24 mL (4 g) NDC Number – Carton: 68982-810-05
48 mL (8 g) NDC Number – Carton: 68982-810-06

In the clinical trials involving CIDP patients, a total of 61 individuals aged over 65 were given Hizentra treatment. After administering Hizentra through subcutaneous injection, the highest levels of the drug in the bloodstream were observed around 2 days later.

Hizentra is approved for patients 2 years and older, while the safety and effectiveness of Privigen have not been determined for patients with PI under 3 years of age. Additionally, Privigen is used to increase platelet counts in patients with chronic immune thrombocytopenic purpura (ITP).